Whether financing startup activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution.
This course provides an understanding of the critical roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Through lectures and case studies, participants learn the importance of well-executed opportunity assessments, the hallmarks of viable business models and strategies, and the key financial vehicles for funding and maintaining companies.
The instructors and expert guest speakers offer insight into the importance of strategic deals in building value in bioscience companies. They discuss how to select and target potential partners; assess risks and current trends; determine value and when to deal; and maintain patent integrity worldwide. Finally, the instructors examine the deal-execution process, including negotiating terms, reaching agreement and developing the contract provisions.
Marketing, business development, legal and scientific professionals working in the bioscience arena as well as potential entrepreneurs will benefit from this interactive course.
Instructors:
Audrey Erbes, Ph.D., Principal, Erbes & Associates,is a marketing professional with more than 25 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive VP and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan. Previously, she held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad, with a special emphasis on Europe and Asia/Pacific/Canada. Topic: "Business Development in the Bioscience Industry"
GILBERT R. MINTZ, Ph.D., is president/owner of GRM Associates, a biotechnology consulting firm with expertise in business development, licensing and strategic planning. With more than 25 years in the biotechnology industry, Dr. Mintz has held corporate management and executive-level business development positions at Genelabs Technologies, Anergen (Corixa), and Cygnus. He has executed technology-platform, corporate and academic collaborations and in/out licensing of late-stage products for partnerships in the U.S., Europe and Japan for such companies as Affymetrix, Aclara and Biota Holdings, Ltd, Facet Biotech. Topic: "Working Your Way Through the Bioscience Licensing Process: Licensing - The Process and Transaction."
Guest Speakers:
Harold (Hal) Etterman, M.B.A., has over 25 years of experience in Finance, Operations and Information Technology, including over ten years serving as a CFO, COO and interim CEO. Hal supports early-stage technology businesses in formulating business strategies, venture funding and the development of strategic alliances. Topic: "Financial Planning and Funding for a Bioscience Venture: New, Emerging and Growing Entities"
Carolyn Feamster, M.B.A., a business strategy and analysis consultant, has over 25 years of experience in the pharmaceutical and biotech arenas including therapeutics, diagnostics and drug delivery systems. She has broad expertise across numerous therapeutic areas and has held positions at Syntex, ALZA, Corixa Corporation, and Clearview Projects, where she was most recently vice president of business strategy and analysis. Topic: "Preparing for and Planning Deals for Maximum Strategic Impact"
Thomas L. Gutshall, chairman as well as co-founder of Cepheid in 1996, was the company's first CEO. He also served as president and COO for CV Therapeutics from 1994 to 1996. Previously, he was the executive vice president for Syntex Corporation and a member of its pharmaceutical executive committee. Topic: "Cepheid: Business Model, Strategy, Plan and Implementation"
Michael G. McCully, M.S. as a Director at Deloitte Recap, consults on deal structuring and valuation for Recap Consulting clients and focuses on top-level analyses of business development activity in the biotech and pharmaceutical industry with top tier pharmaceutical firms, investment concerns, and over thirty biotech companies, ranging from early stage platform companies to late stage drug developers. Prior to Recap, Mike worked with Burrill & Company evaluating investment opportunities for the firm's venture funds and developing strategies for investments in the diagnostic space. Topic: "Biotech Business Development: Where Do We Go From Here"
Jim Fox, Ph.D., J.D, is a patent attorney, Goodwin Proctor LLP, specializing in biotech, pharmaceutical, and medical device patents. Previously, he was an instrumentation company product manager, a biotech research scientist and performed post-doctoral research at UCSF and UCLA. Dr. Fox is an inventor on 8 issued US patents.Topic: "What you Need to Know about Patents Working in Business Development"
